Related Experiment Videos
Phase I study of MVE-2 evaluating toxicity and biologic response modification capability
Abstract:
A total of 21 patients were treated in a phase I trial using the biological response modifier MVE-2, a low molecular weight component of pyran copolymer. All patients received weekly IV MVE-2 infused over 2 h. Proteinuria, sometimes of nephrotic proportions, was the dose limiting toxicity, and was seen with increasing incidence as the cumulative dose of MVE-2 exceeded 2500 mg. Other toxicity with MVE-2 was minimal. Biologic response modification at tolerable doses was inconsistent, although several assays, particularly natural cell-mediated cytotoxicity, indicated enhanced activity at higher dosages of MVE-2. No objective tumor responses were observed. MVE-2 is not useful as a biological response modifier using our initial method of administration, since the dose limiting toxicity occurred at lower levels than were necessary to induce consistent biologic response modification. Following completion of the phase I study, we administered MVE-2 by 30-min infusion to 8 additional patients and did not detect proteinuria, in spite of large cumulative doses. It is possible that alternate schedules of MVE-2 administration could minimize proteinuria and allow the administration of dosages necessary for immunologic modification.
Insights
Biological response modifier MVE-2 caused dose-limiting proteinuria in a phase I trial. Alternate administration schedules may allow for effective immunologic modification by minimizing toxicity.
Area of Science:
- Immunology
- Pharmacology
- Oncology
Background:
- MVE-2, a pyran copolymer component, is a biological response modifier.
- Phase I trials evaluate drug safety and dosage.
- Biological response modifiers aim to enhance the host's immune response against cancer.
Purpose of the Study:
- To assess the safety and tolerability of MVE-2 in cancer patients.
- To determine the dose-limiting toxicity of MVE-2.
- To evaluate the immunomodulatory effects of MVE-2.
Main Methods:
- A phase I clinical trial involving 21 patients treated with MVE-2 intravenously over 2 hours weekly.
- Dose escalation to identify the maximum tolerated dose.
- Monitoring for toxicities, particularly proteinuria.
- Assays to measure changes in immune cell activity, including natural cell-mediated cytotoxicity.
Main Results:
- Proteinuria, sometimes nephrotic, was the dose-limiting toxicity, occurring above 2500 mg cumulative dose.
- Minimal other toxicities were observed.
- Biologic response modification was inconsistent at tolerable doses.
- Enhanced immune activity, particularly cytotoxicity, was noted at higher MVE-2 doses.
- No objective tumor responses were observed.
- Subsequent administration via 30-min infusion in 8 patients showed no proteinuria despite large cumulative doses.
Conclusions:
- MVE-2's initial administration method was limited by dose-limiting proteinuria before achieving consistent immunomodulation.
- Alternate MVE-2 administration schedules, such as shorter infusions, may mitigate proteinuria.
- Further investigation into optimized MVE-2 dosing and schedules is warranted to explore its potential as an immunomodulator.